Association of Local Unit Sampling and Microbiology Laboratory Culture Practices With the Ability to Identify Causative Pathogens in Peritoneal Dialysis-Associated Peritonitis in Thailand

Talerngsak Kanjanabuch1,2,3, Tanittha Chatsuwan4,5, Nibondh Udomsantisuk5, Tanawin Nopsopon6, Pongprat Chapatunakul1, Guttiha Halue7, Pichet Lorviriritrun8, Kittisak Tangjittrong9, Surapong Narenpitak10, Chanchana Boonyakrai11, Sajja Tatiyanupanwong12, Rutchanee Chieochanthanakij13, Worapot Treamtrakonpon14, Uraiwan Parinyasiri15, Niwat Lounseng16, Phichit Songviriyavithaya17, Suchai Sritippayawan18, Somchai Eiam-Ong1, Kriang Tungsanga1, David W. Johnson19,20,21, Bruce Robinson22 and Jeffrey Perl23; on behalf of Thailand PDOPPS steering teams

1Division of Nephrology, Department of Medicine Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2Center of Excellence in Kidney Metabolic Disorders, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3Peritoneal Dialysis Excellent Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; 4Antimicrobial Resistance and Stewardship Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 5Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 6Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 7Department of Medicine, Phayao Hospital, Phayao, Thailand; 8Department of Medicine, Sunpatisitprasong Hospital, Ubon Ratchathani, Thailand; 9Department of Medicine, Pranangklao Hospital, Nonthaburi, Thailand; 10Department of Medicine, Udonthani Hospital, Udon Thani, Thailand; 11Department of Medicine, Taksin Hospital, Bangkok Metropolitan Administration, Bangkok, Thailand; 12Department of Medicine, Chaiyaphum Hospital, Chaiyaphum, Thailand; 13Department of Medicine, Sawanpracharak Hospital, Nakhon Sawan, Thailand; 14Department of Medicine, Chaophya Abhaiphubejhr Hospital, Prachin Buri, Thailand; 15Department of Medicine, Songkhla Hospital, Songkhla, Thailand; 16Department of Medicine, Trang Hospital, Trang, Thailand; 17Department of Medicine, Amnatcharoen Hospital, Amnatcharoen, Thailand; 18Division of Nephrology, Department of Internal Medicine, Siriraj Hospital, Bangkok, Thailand; 19Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia; 20Australasian Kidney Trials Network, University of Queensland, Brisbane, Queensland, Australia; 21Translational Research Institute, Brisbane, Queensland, Australia; 22Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA; and 23St. Michael’s Hospital, Toronto, Ontario, Canada

Introduction: This describes variations in facility peritoneal dialysis (PD) effluent (PDE) culture techniques and local microbiology laboratory practices, competencies, and quality assurance associated with peritonitis, with a specific emphasis on factors associated with culture-negative peritonitis (CNP).

Methods: Peritonitis data were prospectively collected from 22 Thai PD centers between May 2016 and October 2017 as part of the Peritoneal Dialysis Outcomes and Practice Patterns Study. The first cloudy PD bags from PD participants with suspected peritonitis were sent to local and central laboratories for comparison of pathogen identification. The associations between these characteristics and CNP were evaluated.

Results: CNP was significantly more frequent in local laboratories (38%) compared with paired PDE samples sent to the central laboratory (12%, \( P < 0.05 \)). Marked variations were observed in PD center practices, particularly with respect to specimen collection and processing, which often deviated from International Society for Peritoneal Dialysis Guideline recommendations, and laboratory capacities, capabilities, and certification. Lower rates of CNP were associated with PD nurse specimen collection, centrifugation of PDE, immediate transfer of samples to the laboratory, larger hospital size, larger PD unit size, availability of an on-site nephrologist, higher laboratory capacity, and laboratory ability to perform aerobic cultures, undertake standard operating procedures in antimicrobial susceptibilities, and obtain local accreditation.

Conclusion: There were large variations in PD center and laboratory capacities, capabilities, and practices, which in turn were associated with the likelihood of culturing and correctly identifying organisms responsible for causing PD-associated peritonitis. Deviations in practice from International Society for Peritoneal Dialysis guideline recommendations were associated with higher CNP rates.

Kidney Int Rep (2021) 6, 1118–1129; https://doi.org/10.1016/j.ekir.2021.01.010
KEYWORDS: culture-negative peritonitis; ISPD guideline; lab practice; microbiology; peritonitis
© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peritonitis is a major cause of morbidity, technique failure, mortality, and excess health care costs in patients treated with peritoneal dialysis (PD). Identification of the causative microorganism is critical for guiding antimicrobial treatment, optimizing clinical outcomes, promoting antimicrobial stewardship, and minimizing antimicrobial resistance. Culturing the PD effluent (PDE) is key to microbiologic diagnosis, but the yield is highly dependent on laboratory practices. As such, the International Society for Peritoneal Dialysis (ISPD) has recommended that PD centers should set the threshold target of culture-negative peritonitis (CNP) at a level of not more than 15% of peritonitis episodes and provided guidance regarding laboratory practices associated with optimizing yields from cultures.

CNP is defined as clinical features of peritonitis (abdominal pain or cloudy dialysate), dialysate leukocytosis (leukocyte count > 100/µl with > 50% neutrophils), and negative dialysate culture result for any organisms. Rates of CNP previously reported in the literature have been highly variable, ranging from 5% to 41%. To date, microbiology laboratory practices with respect to PDE culture yields have not been comprehensively evaluated. The aim of this study was to describe adherence to the guidelines and variations in facility PDE culture techniques and local microbiology laboratory practices, competency, and quality assurance associated with PD-related infections, with a specific emphasis on factors associated with CNP.

**METHODS**

**Study Design and Population**

The rationale, design, and methods for international and Thailand Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) have been previously published. This prospective cohort study was conducted in 22 PDOPPS centers in Thailand from May 2016 to October 2017. The study was approved by the Chulalongkorn University Institutional Review Board and local ethics committees. To be eligible for inclusion, PD centers had to provide treatment to at least 20 PD patients at the time of selection. Thailand study centers were randomly selected from the complete list of 140 eligible PD facilities in Thailand using stratified random sampling by facility characteristics according to geographic regions, health care regions, hospital categories, and numbers of PD patients and PD nurses.

**Center-Level Characteristics**

Facility-level data using uniform and standardized data collection tools, procedures, and processes were completed by the study coordinator at each participating facility. Facility practices regarding culture technique and microbiology laboratory practices were collected yearly via surveys of PD case managers and microbiology laboratory directors in each facility. Any unclear or inconsistent responses were resolved by direct telephone contact with the study coordinators and laboratory managers. The microbiology laboratory survey consisted of 36 questions covering 6 areas of ongoing competency assessment, including sample collection technique, media and condition use, equipment and instruments, identification techniques and methods, method validation and laboratory control, and training of the laboratory staff (Supplementary Questionnaire).

**Microbiology Analysis**

All cloudy PD bags before antibiotic commencement in consented PD participants were sent to local and central laboratories when peritonitis was suspected. The specimen collections were performed separately and independently from the global PDOPPS. According to individual practices of each facility, 3 to 100 ml of PDE was aliquoted from the bag at the injection port with an aseptic technique for microbiologic culture in local laboratories by the nurse coordinator. The bag with the remaining solution was then placed in an ice-shield box and shipped directly to the central laboratory as soon as possible. Any bags with delayed shipping (>24 hours from the onset of bag collection) were discarded. Peripheral blood cultures may also have been collected at the discretion of the attending physician if they deemed it clinically appropriate (e.g., if the patient was clinically septic). However, the collected blood sample was not required for the central laboratory and not counted in the analysis.

At the central laboratory, 3 bottles of 50 ml of PDE obtained from the submitted PD bags were centrifuged at 3500g for 15 minutes, and the supernatants were discarded. The remaining solution (~5 ml) was mixed with the pellet and injected into BACTEC Plus Aerobic/F and BACTEC Plus Anaerobic/F vials (Becton, Dickinson and Company, Dún Laoghaire, Ireland) as well as spread onto several agar plates, including blood agar, MacConkey agar (Oxoid, Basing-stoke, UK), chocolate agar (Oxoid), and specific agar plates (as needed) for 5 to 7 days at 37 °C for bacterial culture. For fungal culture, the pellet from another 50 ml of centrifuged PDE was streaked on Sabouraud dextrose agar (SDA) and specific agar plates (as needed), then incubated at 25 °C and 37 °C for 15 to 30 days. For mycobacterial culture, the pellet from an additional 50 ml of PDE was inoculated in Ogawa medium slants for 2 months and BACTEC MGIT 960 media for 42 days.

Bacterial pathogens were identified by Gram stain and the VITEK MS system (bioMérieux USA, Hazelwood, MO). Yeast-form fungi were identified by the
API20c AUX kit (bioMérieux, Marcy l’Etoile, France), based on biochemical reactions, and mold-form fungi were classified based on the morphology of their sex spores and conidia. Positive MGIT cultures were examined microscopically to confirm the presence of mycobacteria by using smears stained with Kinyoun stain for detecting acid-fast bacilli. The species from these positive MGIT cultures were then determined by the GenoType Mycobacterium CM and AS assays (Hain Lifescience, Nehren Germany), according to the manufacturer’s instructions.

Any discrepancies in organism identification between 2 laboratories were verified from both ends. The local laboratory was asked to send discordant colonies to the central laboratory to reconfirm the pathogen using the culture technique mentioned earlier and the polymerase chain reaction with 6 different primers. A universal bacterial primer (UFUL/URUL primer12 of the 16S ribosomal RNA [16SrRNA] gene), 2 universal fungal primers (ITS1/ITS4 primer8 of the internal transcribed spacer [ITS] and 5.8SR/LR7 primer10 of the 28S rRNA gene), and 3 universal mycobacterial primers (MYCOGEN-F/MYCOGEN-R11 of 16SrRNA gene, INS1/INS2 primer12, and IS6110-F/IS6110-R13 of the insertion sequence 6110 element) were used.

The reaction mixture with fungal DNA was used as a positive control, and reaction mixture without a template was used as a negative control. The experiments were repeated twice. The purified polymerase chain reaction products were then outsourced for Sanger sequencing service (First BASE Laboratories, Singapore Science Park II, Singapore). The sequencing results were subjected to Basic Local Alignment Search Tool (BLAST; National Center for Biotechnology Information; https://blast.ncbi.nlm.nih.gov/Blast.cgi) search against the GenBank database for homology identities.

Statistical Analysis
Data are presented as frequencies and percentages for categorical variables, mean (SD) for normally distributed continuous variables, and median (interquartile range) for nonnormally distributed continuous variables. Peritonitis-related death was defined as the event that occurred during the 50 days after a peritonitis episode. Hemodialysis (HD) transfer was defined as transfer to HD within 50 days after peritonitis onset, with failure to return to PD within 84 days of modality switch date. Categorical data were compared by the Pearson χ² test and the Fisher exact test, as appropriate. Continuous variables were tested for normality using the Shapiro-Wilk test and histograms. Differences in continuous data were evaluated by unpaired t test for normally distributed data and the Wilcoxon rank sum test for nonnormally distributed data. No data were transformed.

Microbiologic patterns of PDE culture between local laboratories and the central laboratory were compared, and then the discordant organisms between the 2 groups were explored. The event of interest was the CNP rate (episodes/yr), which was compared between facility/laboratory categories with a test for incidence-rate difference with mid-P values adjustment and incidence rate ratios with 95% confidence intervals (CI). All data were analyzed using Stata 16.1 software (StataCorp, College Station, TX). A 2-tailed P value <0.05 was considered statistically significant.

RESULTS
The Disparity of Culture Yield and Microorganism Identification
During the cohort period, there were 360 peritonitis episodes in 241 participants from 22 participating facilities. Of these, 83 episodes from 79 patients were included in the study (Figure 1). All peritonitis episodes occurred after patients had completed PD training and commenced PD. The demographic data, blood chemistries, and 3-month outcomes comparing participants with positive and negative local culture results are summarized in Table 1. The crude peritonitis rate was 0.40 episodes/yr, and the peritonitis rate in the median facility was 0.37 episodes/yr (interquartile range, 0.30, 0.49 episodes/yr). The rates of culture negativity of each facility are illustrated in Figure 2, with the ISPD reference threshold of 15%.

![Figure 1. Patient flow diagram and summary of peritonitis episodes. Remitting peritonitis was defined as a combination of relapsing peritonitis within 3 months from the same or different organisms.](https://image.com/figure1.png)
CNP was significantly more frequent in local laboratories (38%) compared with paired PDE samples sent to the central laboratory (12%, \(P < 0.05\)).

The organisms detected by the central laboratory but not by the local laboratories included fungi (9%), gram-positive bacteria (8%), polymicrobial infection (4%), gram-negative bacteria (3%), and mycobacteria (2%; Table 2). Concordant and discordant culture results between the central laboratory and local laboratories are provided in Tables 2 and 3 and Figure 3. The characteristics and outcomes of patients with local negative culture results and concordant or discordant central laboratory culture results are summarized in Supplementary Table S1.

CNP Rate and Local Laboratory Practice

CNP was significantly less likely with a number of facility practices, including performing sedimentation, early transfer of inoculated bottles to microbiology laboratories, and restriction of specimen collection to PD nurses (Table 4). Facilities belonging to small hospitals (<120 beds), having lower numbers of patients...
treated with PD (<100 cases), having no nephrologist, having smaller laboratory capacity, having limited capability in detection of aerobic organisms, lacking a standard operating procedure in microbial susceptibility, and lacking local accreditation (LA) certificates were associated with higher CNP rates (Table 5).

Sample Preparation and Collection Practice

Most facilities (91%) collected PDE specimens after a dwell time of at least 2 hours. However, 2 facilities

Table 2. Peritoneal dialysis effluents culture yields and concordant and discordant microbial culture results between local and central laboratories

| Variable                  | Local labs (n = 83) | Central lab (n = 83) | Central yes, local yes<sup>a</sup> | Central yes, local no<sup>b</sup> | Central no, local yes<sup>c</sup> |
|---------------------------|---------------------|----------------------|-----------------------------------|----------------------------------|----------------------------------|
| Culture negative          | 32 (38)             | 10 (12)              | 9 (28)                            | 1 (10)                           | 23 (72)                          |
| Gram-positive bacteria     | 29 (35)             | 36 (43)              | 27 (93)                           | 9 (25)                           | 0 (0)                            |
| Coagulase-negative Staphylococcus | 10 (12)     | 10 (12)              | 9 (90)                            | 1 (10)                           | 1 (10)                           |
| Staphylococcus aureus      | 6 (7)               | 6 (7)                | 4 (67)                            | 2 (33)                           | 2 (33)                           |
| Streptococcus spp          | 5 (6)               | 13 (16)              | 5 (100)                           | 8 (62)                           | 0 (0)                            |
| Enterococcus spp           | 5 (6)               | 4 (5)                | 4 (80)                            | 0 (0)                            | 1 (20)                           |
| Others                     | 3 (4)               | 3 (4)                | 1 (33)                            | 2 (67)                           | 2 (67)                           |
| Gram-negative bacteria     | 18 (22)             | 20 (25)              | 15 (83)                           | 5 (25)                           | 3 (17)                           |
| Escherichia Coli           | 4 (5)               | 5 (6)                | 4 (100)                           | 1 (20)                           | 0 (0)                            |
| Enterobacter, Pantoea spp. | 4 (5)               | 3 (4)                | 3 (75)                            | 0 (0)                            | 1 (25)                           |
| Klebsiella pneumoniae      | 1 (1)               | 2 (2)                | 0 (0)                             | 2 (100)                          | 1 (100)                          |
| Acinetobacter spp          | 4 (5)               | 3 (4)                | 2 (50)                            | 1 (33)                           | 2 (50)                           |
| Pseudomonas, Brevundimonas, Burkholderia spp | 3 (4)       | 4 (5)                | 3 (100)                           | 1 (25)                           | 0 (0)                            |
| Others                     | 2 (2)               | 3 (4)                | 2 (100)                           | 1 (33)                           | 0 (0)                            |
| Fungi                      | 1 (1)               | 8 (10)               | 1 (100)                           | 7 (88)                           | 0 (0)                            |
| Yeast                      | 1 (1)               | 3 (4)                | 1 (100)                           | 2 (67)                           | 0 (0)                            |
| Mold-filamentous           | 0 (0)               | 5 (6)                | 0 (0)                             | 5 (100)                          | 0 (0)                            |
| Polymicrobial              | 3 (4)               | 7 (8)                | 3 (100)                           | 4 (57)                           | 0 (0)                            |
| Mycobacterium              | 0 (0)               | 2 (2)                | 0 (0)                             | 2 (100)                          | 0 (0)                            |

<sup>a</sup>The total number of cases where both laboratories had the same result for that row.
<sup>b</sup>The number of cases where the central laboratory disclosed the result listed in the row, but the local laboratories did not.
<sup>c</sup>The number of cases where the local laboratories disclosed the result listed in the row, but the central laboratory did not.

Data are presented as number (%).

Table 3. Discordant microbial culture results between local and central laboratories

| Local laboratories | Central laboratory |
|--------------------|--------------------|
| E faecalis         | S gallolyticus     |
| Streptococcus group D, not enterococcus | S sanguis |
| Streptococcus group D, not enterococcus | S sanguis |
| Alpha-hemolytic streptococcus | S mitis/oralis |
| Unclassified gram-positive cocci | S gallolyticus |
| Enterobacter cloacae | Pantoea spp. |
| Enterobacter spp. | Morganella morganii |

No growth

- Gram positive : streptococci (S gallolyticus [2], S equinus [1], S sanguinis [1], alpha-streptococcus [1]), Staphylococcus aureus (1), A. viridans (1), Micrococcus (1), Bacinillus (1)
- Gram negative : K pneumoniae (2), E coli (1), A baumannii (1), B diminuta (1)
- Mold : A flavus (2), A niger (1), unclassified Aspergillus (1), Simplicillium obclavatum (1)
- Yeast : C albicans (1), C parapsilosis (1), Rhodotorula diminuta (1)
- Mycobacteria : M tuberculosis (2)

(9%) accepted bags with 1-hour dwell times for microbial cultivation if it was the first cloudy bag. Six facilities (27%) did not allow the patients to collect their first cloudy bag at home but instead insisted that they be collected by PD nurses at the centers. For the 16 centers that allowed patients to collect their first cloudy bag at their homes, 4 facilities (25%) taught them to keep the bag in a 4 °C refrigerator until they could bring the sample to their PD centers. Seven facilities (32%) hung the bag for 15 minutes before collecting the sample, and the other 15 facilities (68%) inverted the bag 2 or 3 times before sampling. In 3 facilities (14%), only PD nurses were allowed to collect the PD samples, whereas the other facilities allowed ward nurses or emergency department nurses to collect PD samples if they first met the patient (Table 3).

Only 2 facilities (9%) centrifuged the PDE (50–100 ml) and cultivated the pellet (large-volume culture). The other 20 facilities (91%) used bedside inoculation (13 facilities used 1 bottle, 7 used 2 bottles) with total PDE volumes of 3 to 5 ml (2 facilities), 6 to 10 ml (12 facilities), or 12 to 20 ml (6 facilities). Automated blood culture bottle(s) (10 BACTEC, 6 BacT/Alert, or 3 others) were used in 19 facilities (86%), and 1 facility used in-house prepared blood culture bottles. However, none routinely used anaerobic broth as recommended by the ISPD.

Fifteen facilities (68%) immediately transferred the specimens/inoculated bottles to laboratories. Specimens were left in the ward at room temperature in 6 facilities and at 4 °C in 1 facility until laboratories opened for the
day. Only 5 laboratories (23%) reported that they provided microbiologic services 24 hours a day. Thus, only one-quarter of the facilities followed the ISPD guideline concerning specimen transfer (Tables 4 and 5).

Laboratory Capacity, Capability, and Certification

Two laboratories (9%) received <25 culture specimens/day, and 7 (32%) received >200 culture specimens/day.

Only 2 (9%), 1 (5%), and 6 laboratories (27%) had complete equipment, reagents, and media to culture obligate anaerobes, molds, and mycobacteria, respectively. For example, 9 facilities (41%) used specific fungal media (6 SDA and 3 Mycosel [Becton, Dickinson and Company]), and 21 facilities (95%) used only 35–37 °C incubation temperatures for cultivating fungi. Twelve laboratories (55%) had outsourced specimen processing for mycobacterium and filamentous mold cultures. However, none of the laboratories with competency in cultivating these fastidious organisms autonomously inoculate the specimen in special culture conditions for capturing the organisms unless the clinician specifically requested it, usually in cases of refractory or repeated CNP or if the pathogen was accidentally grown under routine conditions.

Twenty laboratories (91%) performed antimicrobial susceptibility tests for bacteria, and only 2 laboratories (9%) did so with fungi. Fifteen laboratories (68%) performed minimal inhibitory concentration testing (E test and/or automated susceptibility; e.g., VITEK-2, MicroScan [Beckman Coulter, Brea, CA]). Of note, 21 (95%), 17 (77%), and 20 laboratories (91%) used standard operating procedures and manuals in specimen processing, microbial identification, and antimicrobial susceptibility testing, respectively.

Only 6 laboratories (27%) currently held a standard accreditation certification (International Organization for Standardization [ISO] 15189 or College of American Pathologists [CAP]) and LA, 18 laboratories (82%) had LA, and 2 laboratories (10%) lacked any accreditation (Table 5).

DISCUSSION

The present study found CNP occurred in 38% of peritonitis episodes, which was considerably higher than the maximum 15% recommended by ISPD guidelines and significantly more frequent in local laboratories (38%) compared with paired PDE samples sent to the central laboratory (12%, \( P < 0.05 \)). Lower rates of CNP were associated with PD nurse specimen collection, centrifugation of PDE, immediate transfer of samples to the laboratory, larger hospital size, larger PD unit size, availability of an on-site nephrologist, higher laboratory capacity, and laboratory ability to perform aerobic cultures, having a standard operating procedure in antimicrobial susceptibilities, and obtaining LA. Discordant culture results between the central laboratory and local laboratories were also observed in 8 cases of culture-positive peritonitis. There was marked variation in the capacities, capabilities, and practices of local laboratories, with some laboratories lacking accreditation, as well as in reported PDE acquisition and processing techniques.

Although the outcome of CNP is debatable compared with culture-positive peritonitis, the capacity to identify the pathogen in every episode of peritonitis is important for rationalizing antimicrobial treatment and identifying potential sources of infection, thereby improving treatment outcomes and mitigating the risks of relapsing, recurrent, and repeat peritonitis episodes. Fahim et al. reported that CNP had a more favorable outcome than culture-positive peritonitis, whereas the Hong Kong study reported converse outcomes.
Recently, Htay et al. 15 used the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) registry and found that CNP had similar or poorer outcomes than peritonitis due to nonstaphylococcal gram-positive peritonitis but had better outcomes than peritonitis caused by all other organisms.

The median CNP of local facilities was similar to previous reports from Thailand (24%–43%) 5,16–18 and at the upper end of the range reported globally (5%–41%). 2–5 However, such registry and center-specific reports have provided scant details regarding the culture techniques used. Szeto et al. 2 demonstrated that higher CNP rates were associated with sampling by a nonspecialist nurse and previous antibiotic exposure. In contrast, a UK survey 19 found no correlation between center-reported CNP rates and PDE processing technique, sampling volume, or center characteristics. In our study, CNP was associated with facilities that deviated from ISPD guideline recommendations concerning PDE preparation, collection, and handling, had limited facility resources (smaller hospital with no nephrologist on site), and had low facility experience (<100 PD cases). CNP was also associated with limited laboratory capacity and capability in identification of aerobic bacteria, lack of a standard operating procedure in antibiotic susceptibility, and lack of a LA.

Although few studies have explored an association between center-level characteristics and the CNP rate, the association between facility size and technique failure has been well established and confirmed by many large registry-based studies. 20–23 Variations in center adherence to the ISPD peritonitis guidelines have also been well demonstrated in Australian 24 and PDOPPS studies 25; however, their impact on culture-negative rates is obscure.

### Table 4. Associations of peritoneal dialysis effluents culture technique with culture-negative peritonitis in Thailand Peritoneal Dialysis Outcomes and Practice Patterns Study participating sites

| Variable                          | All facilities | Incidence rate, median (IQR), episodes/yr | P value for incidence rate difference | Incidence rate ratio (95% CI) |
|-----------------------------------|----------------|-------------------------------------------|----------------------------------------|-------------------------------|
| Facilities, No.                   | 22             |                                            |                                        |                               |
| PDE acquisition                   |                |                                            |                                        |                               |
| Collection of first cloudy bag    |                |                                            |                                        |                               |
| Yes                               | 16 (73)        | 0.09 (0.06–0.12)                           | 0.09                                   | 0.72 (0.49–1.07)              |
| No                                | 6 (27)         | 0.14 (0.12–0.16)                           | 1.00                                   |                               |
| Dwell time before sampling        |                |                                            |                                        |                               |
| <2 hours                          | 2 (9)          | 0.13 (0.12–0.13)                           | 0.68                                   | 1.13 (0.55–2.10)              |
| ≥2 hours                          | 20 (91)        | 0.10 (0.03–0.16)                           | 1.00                                   |                               |
| Bag treatment                     |                |                                            |                                        |                               |
| Inverted                          | 15 (68)        | 0.11 (0.07–0.15)                           | 0.2                                    | 1.30 (0.86–2.01)              |
| Hanging for 10–15 min             | 7 (32)         | 0.06 (0.04–0.18)                           | 1.00                                   |                               |
| Sampling volume                   |                |                                            |                                        |                               |
| ≤6 ml                             | 2 (9)          | 0.14 (0.11–0.16)                           | 0.35                                   | 1.28 (0.72–2.16)              |
| 6–20 ml                           | 18 (82)        | 0.10 (0.06–0.15)                           | 0.09                                   | 1.00 (Reference)             |
| 50–100 ml                         | 2 (9)          | 0.07 (0.03–0.10)                           | 0.34                                   | 0.34 (0.04–1.26)              |
| Specimen collector                |                |                                            |                                        |                               |
| Restrict to PD nurse              | 3 (14)         | 0.07 (0.04–0.29)                           | <0.001                                 | 0.10 (0.05–0.17)              |
| No restriction                    | 19 (86)        | 0.10 (0.06–0.15)                           | 1.00                                   |                               |
| PDE processing                    |                |                                            |                                        |                               |
| Sedimentation                     |                |                                            |                                        |                               |
| Yes                               | 2 (9)          | 0.07 (0.03–0.10)                           | 0.03                                   | 0.33 (0.07–0.98)              |
| No                                | 20 (91)        | 0.11 (0.07–0.16)                           | 1.00                                   |                               |
| Use of automated bottle(s)        |                |                                            |                                        |                               |
| Yes                               | 19 (86)        | 0.10 (0.06–0.16)                           | 0.19                                   | 1.59 (0.78–3.78)              |
| No                                | 3 (14)         | 0.10 (0.03–0.13)                           | 1.00                                   |                               |
| Use anaerobic bottle              |                |                                            |                                        |                               |
| Yes                               | 0 (0)          | NA                                         | NA                                     | NA                            |
| No                                | 22 (100)       | 0.10 (0.06–0.15)                           | 1.00                                   |                               |
| Specimen or inoculated bottle transfer |            |                                            |                                        |                               |
| Specimen storage during off-hours |                |                                            |                                        |                               |
| No storage                        | 15 (68)        | 0.08 (0.05–0.13)                           | 0.02                                   | 1.00 (Reference)             |
| Storage in room temperature       | 6 (27)         | 0.14 (0.10–0.25)                           | 0.65                                   | 1.56 (1.05–2.30)              |
| Storage in 4 °C refrigerator       | 1 (5)          | 0.11 (0.11–0.11)                           | 1.21                                   | (0.38–2.98)                  |

CI, confidence interval; IQR, interquartile range; NA, nonavailable; PD, peritoneal dialysis, PDE, peritoneal dialysis effluents.

Values are represented as number (%), unless otherwise specified.
Our result affirms the existence of such variation and demonstrates the association of such variations and the CNP rate. Exposure to over-the-counter antibiotics before taking the PDE culture might be another explanation for the high CNP rate in our study. Over-the-counter antibiotics are known to reduce a culture yield of bacteria by half26 and are commonly misused in Thai culture. However, only 16% of the participants with peritonitis in our series had exposure to a previous antibiotic within 1 month before the episode.

To minimize CNP rates, the ISPD guidelines updated in 20161 recommend that bedside inoculation of 5 to 10 ml of PDE in 2 (aerobic and anaerobic) blood culture bottles for bacterial culture should be preferred (Level 1C), and the inoculated bottles should arrive at the laboratory within 6 hours. If this is not possible, the

Table 5. Associations of local facility and laboratory characteristics with culture-negative peritonitis in Thailand Peritoneal Dialysis Outcomes and Practice Patterns Study participating sites

| Variable | All facilities | Culture-negative peritonitis | P value for incidence rate difference | Incidence rate ratio (95% CI) |
|----------|----------------|-----------------------------|--------------------------------------|------------------------------|
|          | Incidence rate, median (IQR), episodes/yr |                            |                                       |                              |
| Facilities, No. | 22 |                            |                                       |                              |
| Facility characteristics |          |                            |                                       |                              |
| Hospital category |          |                            |                                       |                              |
| Small (<120 beds) | 2 (9) | 0.23 (0.16–0.29) | 0.03 | 1.82 (1.04–3.05) |
| Medium (120–500 beds) | 7 (32) | 0.10 (0.05–0.12) | 0.35 | 0.82 (0.52–1.27) |
| Large (>500 beds) | 13 (59) | 0.10 (0.07–0.13) | 1.00 [Reference] |                              |
| PD unit larger than 100 cases |          |                            |                                       |                              |
| Yes | 13 (59) | 0.10 (0.07–0.12) | 0.03 | 0.66 (0.45–0.98) |
| No | 9 (41) | 0.10 (0.05–0.24) | 1.00 [Reference] |                              |
| Bangkok metropolitan region |          |                            |                                       |                              |
| Yes | 5 (23) | 0.05 (0.04–0.10) | 0.18 | 0.67 (0.34–1.22) |
| No | 17 (77) | 0.11 (0.08–0.16) | 1.00 [Reference] |                              |
| Facility age >10 years |          |                            |                                       |                              |
| Yes | 6 (27) | 0.08 (0.04–0.10) | 0.28 | 0.77 (0.46–1.24) |
| No | 16 (73) | 0.12 (0.07–0.18) | 1.00 [Reference] |                              |
| Availability of nephrologist |          |                            |                                       |                              |
| Yes | 19 (86) | 0.10 (0.06–0.13) | 0.02 | 0.58 (0.37–0.95) |
| No | 3 (14) | 0.16 (0.12–0.29) | 1.00 [Reference] |                              |
| Networking in peritonitis treatment |          |                            |                                       |                              |
| Yes | 11 (50) | 0.11 (0.08–0.13) | 0.4 | 0.86 (0.58–1.26) |
| No | 11 (50) | 0.08 (0.04–0.18) | 1.00 [Reference] |                              |
| Laboratory characteristics |          |                            |                                       |                              |
| Laboratory capacity |          |                            |                                       |                              |
| Anaerobic facility | 2 (9) | 0.07 (0.04–0.10) | 0.45 | 0.44 (0.01–2.52) |
| Polymerase chain reaction | 10 (45) | 0.11 (0.04–0.12) | 0.76 | 1.06 (0.71–1.56) |
| MIC (automated or E-test) | 14 (64) | 0.10 (0.05–0.13) | 0.3 | 0.82 (0.56–1.22) |
| Lab workload, c/s specimens/d |          |                            |                                       |                              |
| Small (<50 specimens/d) | 2 (9) | 0.23 (0.16–0.29) | 0.02 | 1.99 (1.07–3.62) |
| Medium (50–200 specimens/d) | 13 (59) | 0.10 (0.06–0.12) | 0.93 | 1.02 (0.65–1.63) |
| Large (>200 specimens/d) | 7 (32) | 0.10 (0.04–0.13) | 1.00 [Reference] |                              |
| Providing 24-hour service |          |                            |                                       |                              |
| Yes | 5 (23) | 0.12 (0.10–0.13) | 0.34 | 1.24 (0.76–1.95) |
| No | 17 (77) | 0.10 (0.06–0.15) | 1.00 [Reference] |                              |
| Lab capability in organism identification |          |                            |                                       |                              |
| Aerobic (minimum) | 20 (91) | 0.10 (0.06–0.13) | 0.01 | 0.51 (0.31–0.87) |
| Anaerobic | 2 (9) | 0.07 (0.04–0.10) | 0.45 | 0.44 (0.01–2.52) |
| Fungus | 1 (5) | 0.04 (0.04–0.04) | 0.3 | 0.36 (0.01–2.05) |
| Mycobacterium | 6 (27) | 0.12 (0.05–0.24) | 0.03 | 1.86 (1.00–2.61) |
| Standard operating procedure |          |                            |                                       |                              |
| Specimen processing | 21 (95) | 0.10 (0.06–0.15) | 0.72 | 1.37 (0.37–11.49) |
| Microbial identification | 17 (77) | 0.10 (0.06–0.13) | 0.07 | 0.68 (0.45–1.05) |
| Antibiotic susceptibility | 20 (91) | 0.10 (0.06–0.13) | 0.01 | 0.51 (0.31–0.87) |
| Lab certification |          |                            |                                       |                              |
| CAP or ISO 15189 with LA | 6 (27) | 0.11 (0.10–0.24) | 0.05 | 1.50 (0.99–2.23) |
| LA | 18 (82) | 0.10 (0.06–0.12) | 0.01 | 0.57 (0.37–0.89) |

CAP, College of American Pathologist; CNR, culture-negative rate; c/s, culture; E-test, episolometer test; IQR, interquartile range; ISO, International Organization for Standardization; LA, local accreditation; MIC, minimum inhibitory concentration; PD, peritoneal dialysis.

Values are represented as number (%), unless otherwise specified.
inoculated culture bottles should ideally be incubated at 37 °C. However, the present study showed that center adherence to this guideline was generally slight. No facilities used anaerobic broth to inoculate PDE. Three-quarters of local laboratories provided microbiologic services only during working hours, indicating that the inoculated bottles would be stored at room temperature (6 centers) or 4 °C (1 center) for more than 6 hours if the specimens were collected after-hours, thereby compromising culture-positive yields of the local laboratories. Refrigeration or freezing may kill or retard the growth of some microorganisms.27

ISPD also recommends that the solid media should be incubated in aerobic, microaerophilic, and anaerobic environments. However, only 2 laboratories (9%) delivered full microbiology laboratory capability, defined as the availability of an anaerobic incubator, proper specimen preparation stations, and appropriate media, including those required for cultivating and isolating obligated anaerobes.

Molds, environmental yeasts, and mycobacteria were only detected by the central laboratory but not at all by local laboratories, confirming the latter’s limited capacity to cultivate these fastidious organisms. This is further supported by the finding that only 2 (9%) and 6 laboratories (27%) had complete equipment, reagents, and media to culture molds and mycobacteria, respectively. Thirteen laboratories (59%) had no availability of fungal-specific media and instead relied on bacterial broth for capturing fungus. Unfortunately, the automated blood culture systems can detect the growth of most pathologic Candida isolates, but not filamentous mold and non-Candida yeast.28 Three laboratories (14%) used Mycosel medium, consisting of soybean meal digest, dextrose, chloramphenicol, and cycloheximide, which is recommended for the isolation of dimorphic fungi and dermatophytes but selectively excludes saprophytes, which are the most common cause of filamentous mold peritonitis.29 Five facilities (23%) used SDA. Most fungal opportunists and pathogenic fungi (both filamentous fungi and yeasts) can grow well on SDA and potato dextrose agar (PDA); however, they need a specific temperature to grow. Typically, molds actively multiply at room temperature (22 °C to 25 °C), whereas yeasts require temperature at 28 °C to 30 °C or 37 °C (for dimorphic fungi).29,30 Some fungal strains may grow poorly or fail to grow on SDA, including Aspergillus niger, A sulphureus, A versicolor, Penicillium corylophilum, P expansum, Fusarium oxysporum, Histoplasma capsulatum, and many strains of Nocardia asteroides.30,31 These strains need alternative agars for growth, including sheep blood agar, nutrient agar, tryptic soy agar, and PDA.31

All facilities but 1 used only 35° to 37 °C incubation temperatures for cultivating bacteria and fungus, such that filamentous mold would likely not be detected. The ISPD guideline states that special culture techniques may be considered for the isolation of unusual organisms (e.g., mycobacteria, filamentous fungus, and other fastidious bacteria) if PDE yields no growth after 3 days and the infection has not resolved; however, no details are provided regarding these special culture techniques. A future revision of the guidelines concerning fastidious pathogen identification is warranted.

In particular, specimens should be inoculated and cultivated in media and conditions that promote the growth of unusual pathogens (particularly molds and mycobacteria) if an episode of CNP is refractory to antibiotics. To fully assess filamentous fungal pathogens, appropriate fungal media should be selected, and inoculated agar should be incubated under 2 temperature conditions (room temperature and 35 °C–37 °C). To increase the yield of mycobacterium detection, specific automated mycobacterium broth (BACTEC 460, MGIT 960, MB/BacT) recommended by the World Health Organization is preferred. Furthermore, inoculation and pathogen isolation should be handled by an experienced, accredited laboratory with a clearly documented standard operating procedure.

Discordant culture results between the central laboratory and local laboratories were observed in 8 cases of culture-positive peritonitis, mostly Streptococcus spp. A falsely interpreted hemolytic pattern of streptococci between partial (alpha, including viridans group streptococci and S pneumoniae) and no hemolysis (gamma, including group D and mutans group streptococci) groups was commonly observed in our study. The degree of partial hemolysis can vary widely with the growth medium used to cultivate the organism and the incubation temperature.33

Automated biochemical methods (VITEK-2, BD Phoenix system, etc.) also had limited capacity in the identification of streptococci, particularly viridans group streptococci, because the systems do not have all streptococci species represented in their databases. Compared with biochemical methods as the reference technique, 10% of the streptococci showed disagreement between the automated biochemical technique and the reference method, and the discordance was higher in viridans group streptococci species (53%).34,35 Falsely subclassified streptococci might not only affect clinical outcomes of peritonitis treatment but was also a proxy of a problem in microbiologic diagnosis in Thailand.

The strength of our study is the use of systematic, comprehensive, and prospective data collection according to robust PDOPPS methodology, which permitted detailed analysis of the associations between
center and laboratory characteristics and practices with culture yield in PD-related peritonitis. Additionally, the study performed paired cultures of the first cloudy bag in both central and local laboratories, thereby permitting a head-to-head comparison of laboratory competency concerning microorganism identification from the same specimen.

However, some limitations are worth mentioning. Firstly, the number of patients with paired PDE samples, the number of Thai participating facilities was relatively small, and the number of large specimen exclusion was large, such that a much larger study would be required to establish other limitations in microbial identification of local laboratories confidently.

Secondly, the results of this study may not be generalized to PD populations outside Thailand in whom the incidence of peritonitis with fastidious organisms is appreciably lower.

Thirdly, the high detection rate of environmental mold raises a concern of specimen contamination during bag transfer. However, our study was well conducted with an orientation provided at all sites on how to collect and handle the specimens with aseptic techniques and conditions. Of interest, colonization of the fungus was observed inside the PD catheter collected from most of the cases with filamentous fungus, and subsequently, cultivation of the removed catheter confirmed its presence, thereby supporting its role as a genuine pathogen. We also tested the fungal cell wall in the PDE and used polymerase chain reaction to confirm cases as true positives.

**CONCLUSION**

CNP rates in Thailand were high. There were large variations in center and laboratory capacities, capabilities, and practices, which were associated with the likelihood of culturing and correctly identifying organisms responsible for causing PD-associated peritonitis. In particular, deviation from ISPD guidelines was associated with CNP rates. Center and laboratory practices should be standardized in line with ISPD guidelines, and all laboratories should receive proper accreditation. Continuous quality improvement processes should be introduced to ensure that these processes are sustained, and patient-important peritonitis outcomes are improved.

**DISCLOSURES**

TK has received consultancy fees from Visterra Inc. as country investigator and received speaking honoraria from AstraZeneca and Baxter Healthcare. JP has received speaking honoraria from AstraZeneca, Baxter Healthcare, DaVita Healthcare Partners, Fresenius Medical Care, Dialysis Clinics Incorporated, and Satellite Healthcare, and has served as a consultant for Baxter Healthcare, DaVita Healthcare Partners, Fresenius Medical Care, and liberDi. DJ has previously received consultancy fees, research grants, speaker’s honoraria, and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from AstraZeneca and AWAK, speaker’s honoraria from Ono, and travel sponsorships from Amgen. All other authors have no financial conflicts of interest to declare. All funders and pharmaceutical companies did not have any role in the study design, data collection, data analysis, data reporting, and the decision to submit for publication.

**ACKNOWLEDGMENTS**

Authors would like to acknowledge contributions of the staffs, nurses, and all investigators who work at participating Thailand PDOPPS centers, including Professor Kearkiat Praditpornsilpa, MD, Chulalongkorn University, Bangkok, Thailand; Areewee Cheawchanwattana, PhD, Khon Kean University; Ms. Piyaporn Towsannang and Kanittha Triamamorphoomwooth, MPHm, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Mrs. Nisa Thongbor, Department of Medicine, Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand; Ms. Nipa Aiyasanon, Division of Nephrology, Department of Internal Medicine, Siriraj Hospital, Bangkok, Thailand; Mrs. Donkum Kaewboonsert, and Mrs. Pensri Uttayotha, Department of Medicine, Phayao Hospital, Phayao, Thailand; Wichai Sopassathit, MD, and Mrs. Salakjit Pitakmongkol, Division of Nephrology, Department of Internal Medicine, Pranangklao Hospital, Nonthaburi, Thailand; Ussanee Poonvivatchaikarn, MD, and Mrs. Bunpring Kaewthong, speaker.

Additional funders include: AstraZeneca, Baxter Healthcare, DaVita Healthcare Partners, Fresenius Medical Care, and liberDi. DJ has previously received consultancy fees, research grants, speaker’s honoraria, and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from AstraZeneca and AWAK, speaker’s honoraria from Ono, and travel sponsorships from Amgen. All other authors have no financial conflicts of interest to declare. All funders and pharmaceutical companies did not have any role in the study design, data collection, data analysis, data reporting, and the decision to submit for publication.

**ACKNOWLEDGMENTS**

Authors would like to acknowledge contributions of the staffs, nurses, and all investigators who work at participating Thailand PDOPPS centers, including Professor Kearkiat Praditpornsilpa, MD, Chulalongkorn University, Bangkok, Thailand; Areewee Cheawchanwattana, PhD, Khon Kean University; Ms. Piyaporn Towsannang and Kanittha Triamamorphoomwooth, MPHm, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Mrs. Nisa Thongbor, Department of Medicine, Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand; Ms. Nipa Aiyasanon, Division of Nephrology, Department of Internal Medicine, Siriraj Hospital, Bangkok, Thailand; Mrs. Donkum Kaewboonsert, and Mrs. Pensri Uttayotha, Department of Medicine, Phayao Hospital, Phayao, Thailand; Wichai Sopassathit, MD, and Mrs. Salakjit Pitakmongkol, Division of Nephrology, Department of Internal Medicine, Pranangklao Hospital, Nonthaburi, Thailand; Ussanee Poonvivatchaikarn, MD, and Mrs. Bunpring Jaroenpattawut, Nephrology Clinic, Nakhon Pathom Hospital, Nakhon Pathom, Thailand; Somphon Buranaosot, MD, Sukit Nilvarangkul, MD, and Ms. Warakoan Saitikan, Bangkok Metropolitan Administration General Hospital, Bangkok, Thailand; Wanida Somboonsilp, MD, Pimpong Wongtrakul, MD, Ms. Ampai Tongpliw, and Ms. Anocha Pullboon, Continuous Ambulatory Peritoneal Dialysis (CAPD) Clinic, Chaoprayayomraj Hospital, Suphanburi, Thailand; Ms. Montha Jankramol, Division of Nephrology, Department of Internal Medicine, Taksin Hospital, Bangkok, Thailand; Mrs. Apinya Wechpradit, Renal Unit, Department of Internal Medicine, Udon Thani Hospital, Udon Thani, Thailand; Ms. Chadarat Kleebsaiyaphum, Nephrology Division, Department of Internal Medicine, Chaiyaphum Hospital, Chaiyaphum, Thailand; Wadsamon Saikong, MD, Mrs. Worauma Panya, and Mrs. Siriwat Thaweeket, CAPD Clinic, Mukdahan Hospital, Mukdahan, Thailand; Sriphrae Uppamai, MD, Jarubut Phisutrattanaporn, MD, and Mrs. Sirirat Sirinual, Department of Internal Medicine, Sukhothai Hospital, Sukhothai, Thailand; Setthapon Panyatong, MD, Puntapong Taruangsri, MD, Mrs. Boontita
Prasertkul, and Ms. Thanchanok Buanet, Kidney Center, Department of Internal Medicine, Nakornping Hospital, Chiang Mai, Thailand; Mrs. Panthira Passorn, Dialysis Unit, Sawanpracharak Hospital, Nakhon Sawan, Thailand; Mrs. Rujira Lukasanprom, Department of Medicine, Trang Hospital, Trang, Thailand; Angsuwarin Wongpiang, MD, and Ms. Metinee Chaithan, CAPD, Pong Hospital, Phayao, Thailand; Mrs. Rachdaporn Phaichan, Department of Medicine, Chaophya Abhaiphubejh Hospital, Prachin Buri, Thailand; Peerapach Rattanasoonton, MD, and Mrs. Wanlaya Thongsiw, Department of Medicine, Trat Hospital, Trat, Thailand; Narumon Lukrat, MD, and Mrs. Sayumporn Thaitrng, CAPD Unit, KhueangNai Hospital, Ubon Ratchatani, Thailand; Mrs. Yupha Laoong, and Mrs. Niparat Pikul, Division of Nephrology, Department of Medicine, Amnatcharoen Hospital, Amnatcharoen, Thailand; and Mrs. Navarat Rukchart, Mrs. Korawee Sukmee, and Mrs. Wandee Chantarungsri, Kidney Diseases Clinic, Department of Internal Medicines, Songkhla Hospital, Songkhla, Thailand. This study was supported by Rachadaphiseksompot Endowment Fund, Chulalongkorn University, Thailand (CU-GRS_61_06_30_01); National Research Council of Thailand, Thailand (IRG5780017). TK is a current recipient of the National Research Council of Thailand. DJ is supported by an Australian National Health and Medical Research Council Practitioner Fellowship.

SUPPLEMENTARY MATERIAL

Table S1. Characteristics and outcomes of patients with local negative cultures.

REFERENCES

1. Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36:481–508.
2. Szeto CC, Wong YH, Chow KIM, et al. The clinical course of culture-negative peritonitis complicating peritoneal dialysis. Am J Kid Dis. 2003;3:567–574.
3. Bunke M, Brier ME, Golper TA. Culture-negative CAPD peritonitis: the Network 9 Study. Adv Perit Dial. 1994;10:174–178.
4. Perl J, Fuller DS, Bieber BA, et al. Peritoneal dialysis-related infection rates and outcomes: results from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Am J Kidney Dis. 2020;76:42–53.
5. Kanjanabuch T, Chancharoenthana W, Katavetin P, et al. The incidence of peritoneal dialysis-related infection in Thailand: a nationwide survey. J Med Assoc Thai. 2011;94(suppl 4):S7–S12.
6. Perl J, Davies SJ, Lambie M, et al. The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): unifying efforts to inform practice and improve global outcomes in peritoneal dialysis. Perit Dial Int. 2016;36:297–307.
7. Kanjanabuch T, PuapatanaKul P, Halue G, et al. Implementation and challenges of PDOPPS in a middle-income country: Thailand experience. Perit Dial Int. 2021.
8. Nilsson WB, Strom MS. Detection and identification of bacterial pathogens of fish in kidney tissue using terminal restriction fragment length polymorphism (T-RFLP) analysis of 16S rRNA genes. Dis Aquat Organ. 2002;48:175–185.
9. White TJ, Bruns T, Lee SJ, et al. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR protocols: a guide to methods and applications. 1st ed. New York: Academic Press; 1990:p:315–322.
10. Vilgalys R. Conserved primer sequences for PCR amplification and sequencing from nuclear ribosomal RNA [Internet] 2004. [cited 2020 Dec 12]. Available at: http://www.biology.duke.edu/fungi/mycolab/primers.htm. Accessed February 24, 2021.
11. Kulski JK, Khinsoe C, Pyczce T, et al. Use of a multiplex PCR to detect and identify Mycobacterium avium and M. intracellular in blood culture fluids of AIDS patients. J Clin Microb. 1995;33:668–674.
12. Van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microb. 1993;31:406–409.
13. Eisenach KD, Donald Cave M, Bates JH, et al. Polymerase chain reaction amplification of a repetitive DNA sequence specific for Mycobacterium tuberculosis. J Infect Dis. 1990;161:977–981.
14. Fahim M, Hawley CM, McDonald SP, et al. Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases. Am J Kidney Dis. 2010;55:690–697.
15. Htay H, Cho Y, Pascoe EM, et al. Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. Perit Dial Int. 2020;40:47–56.
16. Pattanachaiwit N, Gojaseni P, Junrak J, et al. The changing profile of PD-related peritonitis in Thailand: a single centers experience. J Med Assoc Thai. 2011;94(suppl 4):S44–S51.
17. Nakwan N, DissaneeWate P, Lim A, et al. Dialysis-related peritonitis in Southern Thailand. Int J Artif Organs. 2008;31:49–54.
18. Nochaiwong S, Ruengorn C, Koyratkoson K, et al. A clinical risk prediction tool for peritonitis-associated treatment failure in peritoneal dialysis patients. Sci Rep. 2018;8:14797.
19. Odudu A, Turner J, Coomer K, et al. United Kingdom survey of culture-negative peritonitis and dialysate sampling practice. Perit Dial Int. 2016;36:101–117.
20. Afolalu B, Troidle L, Osayimwen O, et al. Technique failure and center size in a large cohort of peritoneal dialysis patients in a defined geographic area. Perit Dial Int. 2009;29:292–296.
21. Huisman RM, Nieuwenhuizen MG, Th de Charro F. Patient-related and centre-related factors influencing technique survival of peritoneal dialysis in The Netherlands. Nephrol Dial Transplant. 2002;17:1655–1660.
22. Schaubel DE, Blake PG, Fenton SSA. Effect of renal center characteristics on mortality and technique failure on peritoneal dialysis. *Kidney Int*. 2001;60:1517–1524.

23. Htay H, Cho Y, Pascoe EM, et al. Multicenter registry analysis of center characteristics associated with technique failure in patients on incident peritoneal dialysis. *Clin J Am Soc Nephrol*. 2017;12:1090–1099.

24. Jose M, Johnson DW, Mudge DW, et al. Peritoneal dialysis practice in Australia and New Zealand: a call to action. *Nephrology*. 2011;16:19–29.

25. Boudville N, Johnson DW, Zhao J, et al. Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study. *Nephrol Dial Transplant*. 2019;34:2118–2126.

26. Driscoll AJ, Deloria Knoll M, Hammitt LL, et al. The effect of antibiotic exposure and specimen volume on the detection of bacterial pathogens in children with pneumonia. *Clin Infect Dis*. 2017;64(suppl 3):S368–S377.

27. Baron EJ, Weinstein MP, Dunne WM, et al. Cumitech: Cumulative Techniques and Procedures. *Clinical Microbiology. Cumitech 1C Blood Cultures IV*. Washington, DC: ASM Press; 2005.

28. Christenson JC, Korgenski EK, Relich RF. Laboratory diagnosis of infection due to bacteria, fungi, parasites, and rickettsiae. In: Long SS, Prober CG, Fischer M, eds. *Principles and Practice of Pediatric Infectious Diseases*. Elsevier Inc; 2018: 1422–1434.e3.

29. Long SS, Prober CG, Fischer M. *Principles and Practice of Pediatric Infectious Diseases*. 5th ed.; 2018. Available at: https://www.sciencedirect.com/book/9780323401814/principles-and-practice-of-pediatric-infectious-diseases. Accessed June 19, 2020.

30. Larone DH. *Medically Important Fungi: A Guide to Identification*. 4th ed. Washington, DC: ASM Press; 2002.

31. Aryal S. Sabouraud Dextrose Agar (SDA)—Composition, Principle, Uses, Preparation and Colony Morphology. Updated 15 August 2019. Available at: https://microbiologyinfo.com/sabouraud-dextrose-agar-sda-composition-principle-uses-preparation-and-colony-morphology/. Accessed June 19, 2020.

32. World Health Organization. WHO guidelines on tuberculosis. Available at: https://www.who.int/publications/guidelines/tuberculosis/en/. Accessed November 25, 2020.

33. Doern CD, Burnham CD. It's not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations. *J Clin Microbiol*. 2010;48:3829–3835.

34. Kikuchi K, Enari T, Totsuka K, et al. Comparison of phenotypic characteristics, DNA-DNA hybridization results, and results with a commercial rapid biochemical and enzymatic reaction system for identification of viridans group streptococci. *J Clin Microbiol*. 1995;33:1215–1222.

35. Hirakata Y, Matsuda J, Nakano M, et al. Evaluation of the BD Phoenix Automated Microbiology System SMICID panel for identification and antimicrobial susceptibility testing of *Streptococcus* spp. *Diagn Microbiol Infect Dis*. 2005;53:169–173.

36. Brigante G, Luzzaro F, Bettaccini A, et al. Use of the Phoenix automated system for identification of *Streptococcus* and *Enterococcus* spp. *J Clin Microbiol*. 2006;44:3263–3267.